Tolerion’s platform technology is based on a major biological phenomenon of immunological tolerance, its importance recognized through 1960 Nobel Prize awarded to Burnet and Medawar. Its proprietary technology uses off-the-shelf, proprietary DNA plasmid to induce antigen-specific immune tolerance to virtually any protein without the need for immunosuppression in a wide range of clinical applications. This targeted and selective approach will lead to improved efficacy, safety and tolerability relative to current therapies.
Currently there are no approved therapies that restore tolerance in autoimmune disease. Our first clinical proof of concept is in type I diabetes with the lead product candidate, TOL-3021. It has completed Phase 2a clinical trial and is poised to enter pivotal trial.